Luigi Costa, Noema Pharma CEO

Noe­ma Phar­ma rais­es $112M Se­ries B to ad­vance CNS dis­or­der pipeline with Roche can­di­dates

Swiss biotech Noe­ma Phar­ma jump­start­ed back in 2020 with a $60 mil­lion Se­ries A fi­nanc­ing round. To­day, it’s wrap­ping up its Se­ries B round with an­oth­er $112 mil­lion to de­vel­op its pipeline of mol­e­cules fo­cused on cen­tral ner­vous sys­tem dis­or­ders.

Noe­ma start­ed out with four clin­i­cal stage as­sets in-li­censed from Roche. The com­pa­ny says it will use this new round of fi­nanc­ing to push for­ward its lead can­di­date basimglu­rant (NOE-101), an mGluR5 in­hibitor which is cur­rent­ly be­ing eval­u­at­ed in Phase IIb clin­i­cal tri­als for se­vere pain in trigem­i­nal neu­ral­gia and seizures in tuber­ous scle­ro­sis com­plex.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.